Aurinia Pharmaceuticals Inc.: what the price is pricing in

The price implies cash-flow growth of 14.6% a year; our model expects 20.0%. The gap is too narrow for a position this quarter. Switch lens below to see the same question asked of earnings, growth, sales and book value.

No published rating for Aurinia Pharmaceuticals Inc.: data-quality checks not passed. The readings below run our models backwards for research and show how trading the gap would have done; they are not a valuation or a rating. The valuation page shows the models and their status.

What growth in cash flow is the price paying for?

The price implies cash-flow growth of 14.6% a year; our model expects 20.0%.

Gap too narrow for a position this quarter

What the price implies What our model expects

Quarters with a position10 long, 1 short, since March 31, 2026

Beat the S&P 5001 of 1100.0% of quarters held

Strategy against the index+0.6%cumulative; worst fall 0.0%

Over time

The growth in owner earnings (free cash flow after stock-based pay) that would justify the share price in our discounted-cash-flow model, against the growth the model itself assumes from the company's record.

Growth our model assumes Growth the price implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

Skill or luck?

In plain English: With only 1 quarters of positions, Aurinia Pharmaceuticals Inc.'s own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	0	—	—	—	—	—	—
Shorts	1	100.0%	+0.6%	+0.6%	+2.5%	—	Too few quarters
All positions	1	100.0%	+0.6%	+0.6%	+2.5%	—	Too few quarters

Each position is measured against the S&P 500 over the same quarter: a long earns the stock's return minus the index's, a short the index's minus the stock's. "A year" compounds the per-quarter results. Evidence: strong at a t-statistic of 2 or more, some from 1.5; "worse" when the result is that far below zero; one company's history is a small sample, so read these alongside the results across all companies.

Every quarter (3)

From	Price paid	Growth the price implies	Growth our model assumes	Position	AUPH	S&P 500
September 30, 2026 (open)	$16.20	14.6%	20.0%	No position	−0.4%	−0.8%
June 30, 2026	$16.97	27.3%	20.0%	No position	−4.6%	+2.4%
March 31, 2026	$14.82	61.9%	20.0%	Short	+14.5%	+15.1%

Price paid: the closing price that day as traded, before any later share split.

What growth in earnings is the price paying for?

The price implies earnings growth of -14.5% a year; our model expects 20.0%.

Market more pessimistic than our model: long this quarter

What the price implies What our model expects

Quarters with a position32 long, 1 short, since March 31, 2025

Beat the S&P 5001 of 333.3% of quarters held

Strategy against the index−2.5%cumulative; worst fall -7.5%

$10,000 became$13,481S&P 500 bought and held: $13,860

Over time

The earnings growth the price-to-earnings ratio requires, against the growth our model assumes. Net income is already after interest, so it is valued at the return shareholders require, plus spare cash (none for banks and insurers, whose cash is funded by deposits and policies), with no debt subtracted.

Growth our model assumes Growth the P/E implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

$10,000 trading the gap vs the S&P 500

StrategyS&P 500, buy and hold Hypothetical, before costs. The strategy holds the S&P 500 and only changes on a signal: it switches into AUPH in long quarters and adds a short of AUPH in short quarters. The gap between the lines is what the signal added or lost.

Skill or luck?

In plain English: With only 3 quarters of positions, Aurinia Pharmaceuticals Inc.'s own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	2	0.0%	−3.8%	−3.8%	−14.5%	—	Too few quarters
Shorts	1	100.0%	+5.4%	+5.4%	+23.6%	—	Too few quarters
All positions	3	33.3%	−0.7%	−0.6%	−3.3%	-0.20	Too few quarters

Every quarter (7)

From	Price paid	Growth the P/E implies	Growth our model assumes	Position	AUPH	S&P 500
September 30, 2026 (open)	$16.20	-14.5%	20.0%	Long	−0.4%	−0.8%
June 30, 2026	$16.97	-11.2%	20.0%	Long	−4.6%	+2.4%
March 31, 2026	$14.82	-13.1%	20.0%	Long	+14.5%	+15.1%
December 31, 2025	$15.95	10.5%	20.0%	No position	−7.1%	−4.4%
September 30, 2025	$11.05	8.6%	13.0%	No position	+44.3%	+2.7%
June 30, 2025	$8.47	11.7%	13.0%	No position	+30.5%	+8.1%
March 31, 2025	$8.04	49.3%	13.0%	Short	+5.3%	+10.8%

Price paid: the closing price that day as traded, before any later share split.

What profit margin is the price paying for?

The price implies an owner-earnings margin of 14.0%; the company has kept 18.8%.

Gap too narrow for a position this quarter

What the price implies What the company delivered

Quarters with a position180 long, 18 short, since December 31, 2021

Beat the S&P 50011 of 1861.1% of quarters held

Strategy against the index−100.0%cumulative; worst fall -100.0%

$10,000 became$0S&P 500 bought and held: $20,395

Over time

The owner-earnings margin (free cash flow after stock pay, as a share of revenue) the price requires at our model's growth, against the margin the company has delivered over three years.

Margin delivered Margin the price implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

$10,000 trading the gap vs the S&P 500

Skill or luck?

In plain English: Across 18 quarters with a position, this lens beat the S&P 500 in 11, by −2.3% a quarter on average. That could easily be chance. One company is a small sample: the results across all companies are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	0	—	—	—	—	—	—
Shorts	18	61.1%	−2.3%	+4.1%	—	-0.22	No reliable evidence
All positions	18	61.1%	−2.3%	+4.1%	—	-0.22	No reliable evidence

Every quarter (19)

From	Price paid	Margin the price implies	Margin delivered	Position	AUPH	S&P 500
September 30, 2026 (open)	$16.20	14.0%	18.8%	No position	−0.4%	−0.8%
June 30, 2026	$16.97	17.0%	11.6%	Short	−4.6%	+2.4%
March 31, 2026	$14.82	15.3%	2.0%	Short	+14.5%	+15.1%
December 31, 2025	$15.95	17.4%	-2.7%	Short	−7.1%	−4.4%
September 30, 2025	$11.05	18.2%	-12.3%	Short	+44.3%	+2.7%
June 30, 2025	$8.47	15.0%	-25.7%	Short	+30.5%	+8.1%
March 31, 2025	$8.04	15.6%	-37.8%	Short	+5.3%	+10.8%
December 31, 2024	$8.98	12.7%	-50.8%	Short	−10.5%	−4.3%
September 30, 2024	$7.33	16.0%	-68.2%	Short	+22.5%	+2.5%
June 30, 2024	$5.71	12.8%	-88.9%	Short	+28.4%	+5.8%
March 31, 2024	$5.01	12.4%	-110.8%	Short	+14.0%	+4.4%
December 31, 2023	$8.99	25.2%	-109.8%	Short	−44.3%	+10.4%
September 30, 2023	$7.77	20.8%	-130.6%	Short	+15.7%	+11.6%
June 30, 2023	$9.68	28.5%	-155.1%	Short	−19.7%	−3.2%
March 31, 2023	$10.96	35.4%	-171.5%	Short	−11.7%	+8.7%
December 31, 2022	$4.32	13.2%	-217.8%	Short	+153.7%	+7.5%
September 30, 2022	$7.52	33.6%	-247.5%	Short	−42.5%	+7.6%
June 30, 2022	$10.05	43.0%	-259.6%	Short	−25.2%	−4.9%
December 31, 2021	$22.87	128.9%	-223.5%	Short	−45.9%	−4.6%

Price paid: the closing price that day as traded, before any later share split.

What return on equity is the price paying for?

The price implies a return on equity of 23.6%; the company earned 66.1%.

Market more pessimistic than our model: long this quarter

What the price implies What the company delivered

Quarters with a position192 long, 17 short, since December 31, 2021

Beat the S&P 50010 of 1952.6% of quarters held

Strategy against the index−100.0%cumulative; worst fall -100.0%

$10,000 became$0S&P 500 bought and held: $17,109

Over time

The return on equity that justifies the price-to-book ratio, (P/B)(r − g) + g with an 8.5% required return and 2.5% long-run growth, against the return the company delivered last year.

Return on equity delivered Return on equity the price implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

$10,000 trading the gap vs the S&P 500

Skill or luck?

In plain English: Across 19 quarters with a position, this lens beat the S&P 500 in 10, by −2.8% a quarter on average. That could easily be chance. One company is a small sample: the results across all companies are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	2	0.0%	−3.8%	−3.8%	−14.5%	—	Too few quarters
Shorts	17	58.8%	−2.7%	+2.7%	—	-0.25	No reliable evidence
All positions	19	52.6%	−2.8%	+2.7%	—	-0.29	No reliable evidence

Every quarter (20)

From	Price paid	Return on equity the price implies	Return on equity delivered	Position	AUPH	S&P 500
September 30, 2026 (open)	$16.20	23.6%	66.1%	Long	−0.4%	−0.8%
June 30, 2026	$16.97	27.2%	65.0%	Long	−4.6%	+2.4%
March 31, 2026	$14.82	23.6%	59.9%	Long	+14.5%	+15.1%
December 31, 2025	$15.95	38.1%	20.6%	Short	−7.1%	−4.4%
September 30, 2025	$11.05	29.7%	17.3%	Short	+44.3%	+2.7%
June 30, 2025	$8.47	23.3%	11.2%	Short	+30.5%	+8.1%
March 31, 2025	$8.04	21.8%	1.5%	Short	+5.3%	+10.8%
December 31, 2024	$8.98	22.7%	-5.8%	Short	−10.5%	−4.3%
September 30, 2024	$7.33	19.9%	-13.3%	Short	+22.5%	+2.5%
June 30, 2024	$5.71	16.2%	-16.7%	Short	+28.4%	+5.8%
March 31, 2024	$5.01	14.0%	-19.9%	Short	+14.0%	+4.4%
December 31, 2023	$8.99	22.2%	-18.9%	Short	−44.3%	+10.4%
September 30, 2023	$7.77	19.5%	-17.8%	Short	+15.7%	+11.6%
June 30, 2023	$9.68	23.7%	-23.1%	Short	−19.7%	−3.2%
March 31, 2023	$10.96	25.6%	-24.5%	Short	−11.7%	+8.7%
December 31, 2022	$4.32	11.2%	-32.0%	Short	+153.7%	+7.5%
September 30, 2022	$7.52	17.6%	-41.5%	Short	−42.5%	+7.6%
June 30, 2022	$10.05	21.6%	-41.1%	Short	−25.2%	−4.9%
March 31, 2022	$12.38	23.2%	-40.8%	Short	−18.8%	−16.1%
December 31, 2021	$22.87	61.6%	-44.0%	Short	−45.9%	−4.6%

Price paid: the closing price that day as traded, before any later share split.

How the test works

At each quarter end since March 2010 we rebuild the models from Aurinia Pharmaceuticals Inc.'s quarters ending at least 90 days earlier (and no more than 200 days before that), using the figures as later filed, including any restatement, and value them at that day's close, adjusted for later share splits and spin-offs so that price and share count are on the same basis. A wide enough gap is a long or a short for one quarter (growth 10 points; margin and return on equity 5 points; a PEG under 0.75 or over 3), measured on total return against the S&P 500. The rules were set before the test. No trading or borrowing costs; today's list of companies. Not investment advice. All companies and the results across them.

Compare with peers

Head to head: AUPH vs IOVA ARVN vs AUPH ADPT vs AUPH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aurinia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aurinia Pharmaceuticals Inc.